Team
The people accountable for the work.
NeuroClearance is a founder-led research and engineering program of NuvoNexus, LLC. This page says who is responsible for what today, who advises us, what we are recruiting for, and where the founder’s prior record ends and this program’s evidence begins.
Founder
David Sherrer
Founder and program lead · accountable for technical direction, program decisions and public statements
David Sherrer has spent more than two decades taking new physical technology from laboratory demonstration through certified manufacturing to acquisition. He founded Nuvotronics in 2008 to commercialize PolyStrata®, a three-dimensional microfabrication process for radio-frequency and millimeter-wave components developed under a DARPA program, and led the company through ISO 9001 and AS9100D certified production for government agencies and defense primes. Cubic Corporation acquired Nuvotronics in March 2019 for approximately $64 million in cash plus up to $8 million in earn-outs. Earlier he founded Haleos and ACT MicroDevices in wafer-level optoelectronic packaging, also taken through production to acquisition. He is a named inventor on more than 125 issued and pending U.S. patent applications across those companies, all assigned to the acquirers. He also leads NuvoNexus, MacroVation and Helicon Defense, which share this program’s emphasis on evidence, trusted manufacturing and disciplined claims.
Results from the founder’s prior companies. They are not claims about NeuroClearance products, certifications or results.
Active contributors
- Engineering support — NuvoNexus and MacroVation engineering teams: assembly, test fixtures and quality systems.
- Regulatory counsel — outside counsel advising on the research-use boundary and the regulatory pathway.
- Patent counsel — outside counsel handling intellectual-property protection.
Named scientific and clinical contributors are listed here with their written consent, role and time commitment as they join.
Advisors
None appointed yet. We list advisors only with written permission, and an advisory role is visibility and counsel, not external validation of the system. Independent verification is a separate, documented step on the roadmap.
Recruiting now · two reviewer roles
- Metrology or controls reviewer. Reviews the bench calibration, timing and uncertainty plan against stated conditions shared under a short agreement. A two- to four-page written plan or a 45-minute call; findings published with your name if you wish.
- Physiology or clinical-methods reviewer. Reviews endpoints and alternative explanations before any study is designed. A short written review or a call; cited when the study design is published.
- Regulatory and study-design input. One call, then a one-page research-readiness checklist. Opens the door to a formal advisory or collaborator role.
A reviewer is not an endorser. Findings are published whether or not they favor us, and no reviewer is named without written consent.
Mission
Evidence that stands up to independent review, produced in the safest and least expensive way possible.
The science of how the brain maintains itself has reached the point where engineering can help answer whether those systems can be measured and, in time, supported. We think the answer deserves rigorous, independent, published work, and that the instruments used to find it should be designed from the first day to be affordable and reproducible, so that others can check our measurements.
We design for rigorous evidence, patient safety and broad access, with a sustainable commercialization model. Any system intended for people will reach them through supervised studies and regulatory review.
Editorial standards
Every statistic on this site carries its source, and every library article lists its primary references and the date it was last reviewed. Drafting, design and software for the program and this site are produced with AI collaborators working under the founder’s direction; a person checks sources, reviews every page before release and signs off on every public statement about the program. Corrections are made promptly and noted on the page.
Institutional home
NeuroClearance operates within MNEOS, an institution built around human judgment, artificial intelligence and a shared record of decisions and results. MNEOS publishes the program’s milestones and open problems; this site explains the science and the work in plain language. Both use the same dated status record.
Press and events
Approved materials for journalists and organizers.
Use the description and biography below as written; they match the program’s actual stage. Please do not describe NeuroClearance as a treatment, a product or a clinical program.
[email protected] with the subject “Press” for interviews, talks or a headshot.
Program description (approved)
NeuroClearance is a research and engineering program of NuvoNexus, LLC, developing research instrumentation to investigate the physiology behind brain fluid transport and waste clearance. The first bench prototype is in development; safety and clinical benefit have not been established. The program publishes an open, source-cited library on brain health at neuroclearance.com.
Short biography (approved)
David Sherrer is the founder of NeuroClearance and of NuvoNexus. He previously founded Nuvotronics, acquired by Cubic Corporation in 2019, and Haleos and ACT MicroDevices, and is a named inventor on more than 125 issued and pending U.S. patent applications, all assigned to the acquirers.
Logo files
Lockup, navy on light · Lockup, cream on dark · Mark, navy · Mark, teal. Keep clear space of at least the mark’s width around the lockup; do not recolor, stretch or add effects.
Our commitments
How we hold ourselves.
Five promises we keep in writing.
We claim benefit only when the evidence and regulators support it.
Today our work is a bench instrument and an open library. Clinical claims come after supervised studies, independent verification and regulatory review.
We present the science as the living field it is.
We summarize studies with their size, their species and their limits, we label what is external literature, what is our own bench result and what is still a hypothesis, and our reading guide shows how to weigh them.
We share designs and protocols through supervised research and under agreement.
Anything involving people belongs in studies with ethical oversight, and technical detail follows the results.
We point people to their clinicians for personal medical questions.
Our library is for understanding; care decisions belong with you and your clinician, and we keep personal health information out of our inbox.
Your ideas stay yours.
If you bring us a collaboration, your background and your work remain yours, and we say so in writing before any substantive discussion.